The contribution of non-conventional T cells and NK cells in the mycobacterial-specific IFNγ response in Bacille Calmette-Guérin (BCG)-immunized infants

PLoS One. 2013 Oct 3;8(10):e77334. doi: 10.1371/journal.pone.0077334. eCollection 2013.

Abstract

Background: The Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine is given to >120 million infants each year worldwide. Most studies investigating the immune response to BCG have focused on adaptive immunity. However the importance of TCR-gamma/delta (γδ) T cells and NK cells in the mycobacterial-specific immune response is of increasing interest.

Methods: Participants in four age-groups were BCG-immunized. Ten weeks later, in vitro BCG-stimulated blood was analyzed for NK and T cell markers, and intracellular IFNgamma (IFNγ) by flow cytometry. Total functional IFNγ response was calculated using integrated median fluorescence intensity (iMFI).

Results: In infants and children, CD4 and CD4-CD8- (double-negative (DN)) T cells were the main IFNγ-expressing cells representing 43-56% and 27-37% of total CD3+ IFNγ+ T cells respectively. The iMFI was higher in DN T cells compared to CD4 T cells in all age groups, with the greatest differences seen in infants immunized at birth (p=0.002) or 2 months of age (p<0.0001). When NK cells were included in the analysis, they accounted for the majority of total IFNγ-expressing cells and, together with DN Vδ2 γδ T cells, had the highest iMFI in infants immunized at birth or 2 months of age.

Conclusion: In addition to CD4 T cells, NK cells and DN T cells, including Vδ2 γδ T cells, are the key populations producing IFNγ in response to BCG immunization in infants and children. This suggests that innate immunity and unconventional T cells play a greater role in the mycobacterial immune response than previously recognized and should be considered in the design and assessment of novel tuberculosis vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptive Immunity
  • Adult
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / immunology*
  • CD4-Positive T-Lymphocytes / classification
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / classification
  • CD8-Positive T-Lymphocytes / cytology
  • CD8-Positive T-Lymphocytes / immunology*
  • Child, Preschool
  • Female
  • Humans
  • Immunity, Innate
  • Immunophenotyping
  • Infant
  • Interferon-gamma / blood*
  • Killer Cells, Natural / classification
  • Killer Cells, Natural / cytology
  • Killer Cells, Natural / immunology*
  • Male
  • Tuberculosis / immunology
  • Tuberculosis / prevention & control*
  • Vaccination*

Substances

  • BCG Vaccine
  • Interferon-gamma

Grants and funding

This study was supported by a project grant from the Australian National Health and Medical Research Council (NHMRC grant no. 546,486), and by grants from the John Burge Trust, the Myer Foundation, the Aranday Foundation, and the Murdoch Children’s Research Institute (http://www.mcri.edu.au). NR was supported by Fellowship awards from the European Society for Paediatric Infectious Diseases (http://www.espid.org) and scholarships from The University of Melbourne. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.